Warfarin-5-FU interaction - A consecutive case series

被引:47
作者
Kolesar, JM
Johnson, CL
Freeberg, BL
Berlin, JD
Schiller, JH
机构
[1] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA
[2] Univ Wisconsin, Sch Med, Madison, WI USA
[3] William S Middleton Mem Vet Adm Med Ctr, Nursing Serv, Madison, WI 53705 USA
[4] Univ Cincinnati, Adjunct Ambulatory Care Fac, Cincinnati, OH USA
[5] Vanderbilt Univ, Med Ctr, Div Hematol Oncol, Nashville, TN USA
来源
PHARMACOTHERAPY | 1999年 / 19卷 / 12期
关键词
D O I
10.1592/phco.19.18.1445.30897
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Five patients from a single institution received concomitant warfarin and 5-fluorouracil (5-FU) during a 3-year period. The mean weekly warfarin dose before starting chemotherapy was 40.66 mg and during chemotherapy it was 24 mg (p=0.0026). All patients required a warfarin dosage reduction (range 18-74%, mean 44%). Two patients were hospitalized, one with a major retroperitoneal bleed, the other for fresh-frozen plasma administration and observation. Maximum international normalized ratios (INRs) ranged from 3.66-23.7. This series confirms a common, clinically significant interaction between warfarin and 5-FU. An interaction between capecitabine, the orally available prodrug of S-FU, and warfarin also has been reported. We recommend weekly monitoring of prothrombin time and INR for all patients receiving concomitant warfarin and 5-FU or capecitabine.
引用
收藏
页码:1445 / 1449
页数:5
相关论文
共 18 条
  • [1] Modulation of the expression of constitutive rat hepatic cytochrome P450 isozymes by 5-fluorouracil
    Afsar, A
    Lee, C
    Riddick, DS
    [J]. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1996, 74 (02) : 150 - 156
  • [2] BENEDETTI F, 1999, IMPORTANT PRESCRIBIN
  • [3] Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
    Blum, JL
    Jones, SE
    Buzdar, AU
    LoRusso, PM
    Kuter, I
    Vogel, C
    Osterwalder, B
    Burger, HU
    Brown, CS
    Griffin, T
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) : 485 - 493
  • [4] BOOTH BW, 1981, NEW ENGL J MED, V305, P170
  • [5] Brown MC, 1997, PHARMACOTHERAPY, V17, P631
  • [6] RELIANCE ON PROTHROMBIN TIME RATIOS CAUSES SIGNIFICANT ERRORS IN ANTICOAGULATION THERAPY
    BUSSEY, HI
    FORCE, RW
    BIANCO, TM
    LEONARD, AD
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (02) : 278 - 282
  • [7] CHLEBOWSKI RT, 1982, CANCER RES, V42, P4827
  • [8] Hemostasis and malignancy
    Francis, JL
    Biggerstaff, J
    Amirkhosravi, A
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1998, 24 (02) : 93 - 109
  • [9] Mechanism of action, clinical effectiveness, and optimal therapeutic range
    Hirsh, J
    Dalen, JE
    Anderson, DR
    Poller, L
    Bussey, H
    Ansell, J
    Deykin, D
    Brandt, JT
    [J]. CHEST, 1998, 114 (05) : 445S - 469S
  • [10] Human P450 metabolism of warfarin
    Kaminsky, LS
    Zhang, ZY
    [J]. PHARMACOLOGY & THERAPEUTICS, 1997, 73 (01) : 67 - 74